Detect cancer when it matters
the most—Because everyone
deserves a fighting chance.

The key to managing cancer is early detection. ClearNote Health makes this possible by finding signals of cancer in your blood early, when treatment is the most effective.

Learn More
;

Our Approach

ClearNote Health’s proprietary epigenomic platform and cell-free DNA-based assays measure dynamic biological changes in cells to provide an early signal of a developing cancer.

See Our Platform

Our Tests

ClearNote Health focuses on cancers with high mortality rates for which there are no or very limited detection options.

Learn About Our Tests

Recent News

We are proud of the clinical evidence, R&D achievements, and our five-year-long company development as Bluestar Genomics. Now, as a commercial-stage company, ClearNote Health continues to drive innovation in non-invasive cancer detection, with patient needs at the core of everything we pursue.
View All

October 31, 2024

Avantect Pancreatic Cancer Test Cost-Effective When Used as a Surveillance Tool in High-Risk Patients Newly Diagnosed with Diabetes

Learn More

September 26, 2024

Avantect Ovarian Cancer Test Receives CPT Code and Preliminary Payment Determination from the Centers for Medicare and Medicaid Services

Learn More

March 26, 2024

New Data Show ClearNote Health’s Epigenomic Platform Provides a Novel Tissue-Free, Liquid Biopsy-Based Approach to Identify Potential Predictive Biomarker Candidates to Radioligand Therapy Response in Patients With Pancreatic Neuroendocrine Tumors

Learn More

Join Our Team and
Make a Difference

View Job Openings